MedTrace Logo

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.

NCT06432764 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-04-14

No results posted yet for this study

Summary

The purpose of this study is to measure the changes in intestinal uptake of radioligand \[11C\]AZ14132516 following multiple doses of AZD7798 in participants with Crohn's disease.

Conditions

  • Crohn Disease

Interventions

DRUG

AZD7798

Each participating patient will receive the study drug as specified in the study protocol.

DRUG

[11C]AZ14132516

A single microdose (≤ 10 μg) of radiopharmaceutical \[11C\]AZ14132516 will be extemporaneously prepared and administered to each participant prior to each PET examination

Sponsors & Collaborators

Principal Investigators

  • Maria Creignou · Karolinska University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-16
Primary Completion
2026-03-27
Completion
2026-03-27
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06432764 on ClinicalTrials.gov